Ad
related to: erbitux for head cancer- Squamous Cell Carcinoma
See the Causes & Treatment Options.
Access Our Free Guide Today.
- Thyroid Cancer
Access Our Free Treatment Guide.
Understand What to Expect.
- Oral Cancer
Have You Been Diagnosed?
See What Treatment Option Is Best.
- Head & Neck Cancer Care
Many Available Treatment Options.
Specially Tailored Treatment Plans.
- Squamous Cell Carcinoma
Search results
Results from the WOW.Com Content Network
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
Abigail Burroughs was a college student diagnosed with head and neck cancer. During the later phases of her treatment, Abigail's father, Frank Burroughs, formed an organization, the Abigail Alliance for Better Access to Developmental Drugs and sued the FDA for access to Erbitux.
Antibody 225 (commercially known as Cetuximab, or Erbitux) against the receptor for epidermal growth factor was approved by the United States Food and Drug Administration for treatment of colon cancer in 2004 and for head and neck cancer in 2006.
Cetuximab (trade name: Erbitux ) is a recombinant chimeric monoclonal antibody designed to treat metastatic colorectal cancer and head and neck cancer. [14] In numerous cancers, the epidermal growth factor receptor (EGFR) is often inappropriately activated and overexpressed in cancer cells, leading to uncontrolled cell growth. [15]
Cetuximab: IV: EGFR inhibitor. Squamous cell head and neck cancer or EGFR-positive and KRAS wild-type metastatic colorectal cancer. Infusion-related reactions, skin ...
The identification of EGFR as an oncogene has led to the development of anticancer therapeutics directed against EGFR (called "EGFR inhibitors", EGFRi), including gefitinib, [28] erlotinib, [29] afatinib, brigatinib and icotinib [30] [31] for lung cancer, and cetuximab for colon cancer.
Get breaking news and the latest headlines on business, entertainment, politics, world news, tech, sports, videos and much more from AOL
Globally, head and neck cancer accounts for 650,000 new cases of cancer and 330,000 deaths annually on average. In 2018, it was the seventh most common cancer worldwide, with 890,000 new cases documented and 450,000 people dying from the disease. [12] The risk of developing head and neck cancer increases with age, especially after 50 years.
Ad
related to: erbitux for head cancer